Public Employees Retirement System of Ohio purchased a new stake in Pieris Pharmaceuticals Inc (NASDAQ:PIRS) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 21,704 shares of the biotechnology company’s stock, valued at approximately $110,000.

A number of other hedge funds also recently bought and sold shares of PIRS. A.R.T. Advisors LLC acquired a new stake in Pieris Pharmaceuticals in the 1st quarter valued at about $103,000. Marshall Wace LLP acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at about $118,000. Fox Run Management L.L.C. acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at about $124,000. MetLife Investment Advisors LLC acquired a new stake in Pieris Pharmaceuticals in the 1st quarter valued at about $141,000. Finally, Bowling Portfolio Management LLC acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at about $156,000. 64.93% of the stock is currently owned by institutional investors.

PIRS stock opened at $5.42 on Thursday. The stock has a market capitalization of $302.59 million, a price-to-earnings ratio of -13.55 and a beta of 1.62. Pieris Pharmaceuticals Inc has a 1 year low of $4.43 and a 1 year high of $9.75.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). Pieris Pharmaceuticals had a negative net margin of 22.38% and a negative return on equity of 27.81%. The company had revenue of $11.69 million during the quarter, compared to analyst estimates of $13.46 million. Equities research analysts expect that Pieris Pharmaceuticals Inc will post -0.49 earnings per share for the current fiscal year.

In other Pieris Pharmaceuticals news, Director Christopher P. Kiritsy bought 5,000 shares of the business’s stock in a transaction dated Friday, September 14th. The shares were acquired at an average price of $5.11 per share, with a total value of $25,550.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $51,100. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 5.07% of the stock is currently owned by company insiders.

A number of research firms have issued reports on PIRS. BidaskClub raised Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright set a $12.00 price target on Pieris Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, September 4th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $12.33.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Story: Dividend Aristocrat Index

Want to see what other hedge funds are holding PIRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pieris Pharmaceuticals Inc (NASDAQ:PIRS).

Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.